
Cybin (CYBN) Stock Forecast & Price Target
Cybin (CYBN) Analyst Ratings
Bulls say
Cybin Inc. has demonstrated strong clinical execution and commercial groundwork, positioning the company favorably ahead of two significant readouts slated for 2026, indicating robust potential in the mental health therapeutics market. The completion of enrollment in the Phase 2 trial for generalized anxiety disorder (GAD) and ongoing advancements in the Phase 3 program for major depressive disorder (MDD) underscore Cybin’s commitment to progressing its innovative therapies. Additionally, the collaboration with ThermoFisher for manufacturing support and their integration into the Osmind clinic network exemplify Cybin's strategic initiatives aimed at enhancing operational efficiency and market readiness.
Bears say
The financial outlook on Cybin Inc. is negatively impacted by several fundamental risks associated with the development of neuropsychiatric therapies, including the potential for clinical trial failures and the unproven safety and efficacy of its proprietary psychedelic compounds. Changes in the discounted cash flow (DCF) model, primarily due to recent dilution from capital raises, have led to a significant reduction in the company's price target, which signals concerns over its financial health and future profitability. Additionally, challenges related to regulatory approval, intellectual property protection, and the commercialization of its products further compound the uncertainty surrounding Cybin's ability to succeed in a highly competitive biopharmaceutical market.
This aggregate rating is based on analysts' research of Cybin and is not a guaranteed prediction by Public.com or investment advice.
Cybin (CYBN) Analyst Forecast & Price Prediction
Start investing in Cybin (CYBN)
Order type
Buy in
Order amount
Est. shares
0 shares